Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Watch comet C/2026 A1 plunge toward the sun online this week - 2Step into Nature: A Survey of \Handling Trails with Solace\ Climbing Shoes
- 3Sheinelle Jones will cohost fourth hour of 'Today' with Jenna Bush Hager: Here's what to know about her
- 45 Eating routine Well disposed Snacks to Keep You Fulfilled
- 5Artemis 2 astronauts see Earth in the rear-view mirror | Space photo of the day for April 3, 2026
- Iranian-linked drone attack kills Kurdish couple in northern Iraq
- 'A perfect storm': Airlines cut flights and increase airfares as jet fuel price spikes
- The Best Computer games for Multiplayer Fun
- Figure out How to Put resources into Lab Precious stones
- 'Hero' who wrestled gun from Bondi shooter named as Ahmed al Ahmed
- EU waters down plans to end new petrol and diesel car sales by 2035
- Kiev declares energy emergency after Russian attacks amid winter cold
- Sydney Sweeney is returning in 'The Housemaid's Secret': What to know about 'The Housemaid' sequel
- The most effective method to Shield Your Gold Ventures: Procedures and Precautionary measures
